- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Immatics NV (IMTX)
Immatics NV stock price live, this page displays NASDAQ IMTX stock exchange data. View the IMTX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Immatics NV real time stock price chart below.
What Is the Immatics NV Stock Price Today?
The Immatics NV stock price today is 6.720.
What Is the Stock Symbol for Immatics NV?
The stock symbol for Immatics NV is "IMTX."
What Stock Exchange Does Immatics NV Trade On?
Immatics NV is listed and trades on the NASDAQ stock exchange.
Is Immatics NV a Good Stock to Buy?
Determining whether Immatics NV, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the IMTX quote. (ISIN: NL0015285941)
What Is the Immatics NV Stock Price Today?
The Immatics NV stock price today is 6.720.
What Is the Stock Symbol for Immatics NV?
The stock symbol for Immatics NV is "IMTX."
What Stock Exchange Does Immatics NV Trade On?
Immatics NV is listed and trades on the NASDAQ stock exchange.
Is Immatics NV a Good Stock to Buy?
Determining whether Immatics NV, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the IMTX quote. (ISIN: NL0015285941)
6.720
+0.300(+4.67%)
Real-time Data·
Fair Value
An estimate of a Immatics NV's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
6.350
6.760
52 wk Range
6.090
12.410
IMTX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Immatics NV's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
6.3506.760
52 wk Range
6.09012.410
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
IMTX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Immatics NV's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
16.400
Upside
+144.05%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
2 analysts have revised their earnings upwards for the upcoming period
Immatics NV receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Immatics NV receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Why is Immatics stock climbing today?- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Analyst Ratings
9 Buy
0 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 16.400
(+144.05% Upside)
Earnings
Latest Release
Nov 10, 2026
EPS / Forecast
-0.50 / -0.45
Revenue / Forecast
6.9M / 10.88M
Compare IMTX to Peers and Sector
Metrics to compare | IMTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIMTXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.4x | −3.5x | −0.2x | |
PEG Ratio | 0.03 | −0.01 | 0.00 | |
Price/Book | 1.8x | 1.1x | 2.6x | |
Price / LTM Sales | 17.9x | 3.9x | 2.8x | |
Upside (Analyst Target) | 145.5% | 461.8% | 62.3% | |
Fair Value Upside | Unlock | 2.3% | 8.2% | Unlock |
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna’s PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Immatics NV (IMTX) Stock Price Today?
The Immatics NV stock price today is 6.720 USD.
What Stock Exchange Does Immatics NV Trade On?
Immatics NV is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Immatics NV?
The stock symbol for Immatics NV is "IMTX."
What Is the Immatics NV (IMTX) Afterhours Price Today? (Afterhours variable test: 6.380) Current Date: Nov 11, 2026
After hours price: 6.380. After hours price change (units): -0.040. Price change percentage: -0.620%
What Is the Immatics NV Market Cap?
As of today, Immatics NV market cap is 919.920M USD.
What Is Immatics NV's Earnings Per Share (TTM)?
The Immatics NV EPS (TTM) is -1.92.
When Is the Next Immatics NV Earnings Date?
Immatics NV will release its next earnings report on Mar 24, 2027.
From a Technical Analysis Perspective, Is IMTX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Immatics NV Stock Split?
Immatics NV has split 0 times.
How Many Employees Does Immatics NV Have?
Immatics NV has 704 employees.
What is the current trading status of Immatics NV (IMTX)?
As of Nov 11, 2026, Immatics NV (IMTX) is trading at a price of 6.720 USD, with a previous close of 6.420 USD. The stock has fluctuated within a day range of 6.350 USD to 6.760 USD, while its 52-week range spans from 6.090 USD to 12.410 USD.
What Is Immatics NV (IMTX) Price Target According to Analysts?
The average 12-month price target for Immatics NV is 16.400 USD, with a high estimate of 21 USD and a low estimate of 11.8 USD. 9 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +144.05% Upside potential.
What Is the IMTX Premarket Price?
IMTX's last pre-market stock price is 6.300 USD. The pre-market share volume is 3,600.000, and the stock has decreased by -0.120, or -1.870%.
What Is the IMTX After Hours Price?
IMTX's last after hours stock price is 6.380 USD, the stock has decreased by -0.040, or -0.620%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.